

STEVE SISOLAK  
Governor



RICHARD WHITLEY, MS  
Director

SUZANNE BIERMAN, JD, MPH  
Administrator

DEPARTMENT OF HEALTH AND HUMAN SERVICES  
DIVISION OF HEALTH CARE FINANCING AND POLICY  
1100 East William Street, Suite 101  
Carson City, Nevada 89701  
Telephone (775) 684-3676 • Fax (775) 687-3893  
<http://dhcfp.nv.gov>

**NOTICE OF PUBLIC MEETING – PHARMACY AND THERAPEUTICS COMMITTEE**

**AGENDA**

**Date of Publication:** May 13, 2019

**Date and Time of Meeting:** June 27, 2019 at 1:00 PM

**Name of Organization:** The State of Nevada, Department of Health and Human Services (DHHS), Division of Health Care Financing and Policy (DHCFP)

**Place of Meeting:** Springs Preserve  
333 S. Valley View Blvd.  
Las Vegas, Nevada 89107

**Please check with staff to verify room location**

**Place of Meeting:** OptumRx Office  
9850 Double R Blvd., Suite 200  
Reno, Nevada 89521

**Webinar Registration:** <https://optum.webex.com/optum/onstage/g.php?MTID=e0edf79766bec040e566d3238904e67e7>

**OR**

[www.webex.com](http://www.webex.com), select “Join,” enter Meeting Number 646 055 536, your name and email and then select, “Join.”

A Password should not be necessary, but if asked, enter “Medicaid1!”

**OR**

**Audio Only:** (763) 957-6300

Event Number: 646 055 536

Follow the instructions that appear on your screen to join the teleconference. Audio will also be broadcast over the internet (VoIP).

Items may be taken out of order.  
Items may be combined for consideration by the public body.  
Items may be pulled or removed from the agenda at any time.

**Public comment is limited to five minutes per individual, organization or agency, but may be extended at the discretion of the Chairperson.**

## **AGENDA**

- 1. Call to Order and Roll Call**
- 2. Public Comment**
- 3. Administrative**
  - a. **For Possible Action:** Review and Approve Meeting Minutes from March 28, 2019
  - b. Status Update by the DHCFP
    1. Public Comment
- 4. Proposed New Drug Classes**
  - a. Neurological Agents – Antiparkinsonian Agents – Dopamine Precursors
    1. Public Comment
    2. Drug Class Review Presentation – OptumRx
    3. **For Possible Action:** Committee Discussion and Action
      - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
      - b. Identify Exclusions/Exceptions for Certain Patient Groups
    4. Presentation of Recommendations for the Preferred Drug List (PDL) Inclusion by OptumRx and the DHCFP
    5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- 5. Established Drug Classes Being Reviewed Due to the Release of New Drugs**
  - a. Analgesics – Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

1. Public Comment
  2. Drug Class Review Presentation – OptumRx
  3. **For Possible Action:** Committee Discussion and Action
    - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
    - b. Identify Exclusions/Exceptions for Certain Patient Groups
  4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
  5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- b. Biologic Response Modifiers – Multiple Sclerosis Agents – Injectable
1. Public Comment
  2. Drug Class Review Presentation – OptumRx
  3. **For Possible Action:** Committee Discussion and Action
    - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
    - b. Identify Exclusions/Exceptions for Certain Patient Groups
  4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
  5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- c. Biologic Response Modifiers – Multiple Sclerosis Agents – Oral
1. Public Comment
  2. Drug Class Review Presentation – OptumRx
  3. **For Possible Action:** Committee Discussion and Action
    - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
    - b. Identify Exclusions/Exceptions for Certain Patient Groups
  4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
  5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- d. Dermatological Agents – Topical Analgesics
1. Public Comment
  2. Drug Class Review Presentation – OptumRx
  3. **For Possible Action:** Committee Discussion and Action
    - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
    - b. Identify Exclusions/Exceptions for Certain Patient Groups

4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
  5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- e. Neurological Agents – Anticonvulsants
1. Public Comment
  2. Drug Class Review Presentation – OptumRx
  3. **For Possible Action:** Committee Discussion and Action
    - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
    - b. Identify Exclusions/Exceptions for Certain Patient Groups
  4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
  5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- f. Ophthalmic Agents – Antiglaucoma Agents
1. Public Comment
  2. Drug Class Review Presentation – OptumRx
  3. **For Possible Action:** Committee Discussion and Action
    - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
    - b. Identify Exclusions/Exceptions for Certain Patient Groups
  4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
  5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- g. Psychotropic Agents – ADHD Agents
1. Public Comment
  2. Drug Class Review Presentation – OptumRx
  3. **For Possible Action:** Committee Discussion and Action
    - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
    - b. Identify Exclusions/Exceptions for Certain Patient Groups
  4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
  5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL

- h. Respiratory Agents – Long-acting/Maintenance Therapy
  - 1. Public Comment
  - 2. Drug Class Review Presentation – OptumRx
  - 3. **For Possible Action:** Committee Discussion and Action
    - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
    - b. Identify Exclusions/Exceptions for Certain Patient Groups
  - 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
  - 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL

**6. Established Drug Classes**

- a. Cardiovascular Agents – Antihypertensive Agents – Vasodilators – Oral
  - 1. Public Comment
  - 2. Drug Class Review Presentation – OptumRx
  - 3. **For Possible Action:** Committee Discussion and Action
    - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
    - b. Identify Exclusions/Exceptions for Certain Patient Groups
  - 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
  - 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
  
- b. Dermatological Agents – Topical Anti-inflammatory Agents – Immunomodulators: Topical
  - 1. Public Comment
  - 2. Drug Class Review Presentation – OptumRx
  - 3. **For Possible Action:** Committee Discussion and Action
    - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
    - b. Identify Exclusions/Exceptions for Certain Patient Groups
  - 4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
  - 5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
  
- c. Hormones and Hormone Modifiers – Antidiabetic Agents – Insulins (Vials, Pens and Inhaled)
  - 1. Public Comment

2. Drug Class Review Presentation – OptumRx
  3. **For Possible Action:** Committee Discussion and Action
    - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
    - b. Identify Exclusions/Exceptions for Certain Patient Groups
  4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
  5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- d. Psychotropic Agents – Antidepressants – Selective Serotonin Reuptake Inhibitors (SSRIs)
1. Public Comment
  2. Drug Class Review Presentation – OptumRx
  3. **For Possible Action:** Committee Discussion and Action
    - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
    - b. Identify Exclusions/Exceptions for Certain Patient Groups
  4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
  5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- e. Respiratory Agents – Short-Acting/Rescue Therapy
1. Public Comment
  2. Drug Class Review Presentation – OptumRx
  3. **For Possible Action:** Committee Discussion and Action
    - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
    - b. Identify Exclusions/Exceptions for Certain Patient Groups
  4. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
  5. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
7. **Report by OptumRx on New Drugs to Market, New Generic Drugs to Market and New Line Extensions**
8. **Closing Discussion**
- a. Public Comments on Any Subject
  - b. Date and Location of the Next Meeting
  - c. Adjournment

---

Notice of this public meeting and draft copies of the changes will be available on or after the date of this notice at the DHCFP Web site at <http://dhcfp.nv.gov> and [notice.nv.gov/](http://notice.nv.gov). The agenda posting of this meeting can be viewed at the follow locations: Carson City Central Office; Las Vegas District Office; Reno District Office; Elko District Office; Nevada State Library; Carson City Library; Churchill County Library; Las Vegas Library; Douglas County Library; Elko County Library; Esmeralda County Library; Lincoln County Library; Lyon County Library; Mineral County Library; Tonopah Public Library; Pershing County Library; Goldfield Public Library; Eureka Branch Library; Lander County Library; Storey County Library; Washoe County Library; and White Pine County Library and may be reviewed during normal business hours.

If requested in writing, a copy of the proposal will be mailed to you. Requests and/or written comments on the proposed changes may be sent to the DHCFP, 1100 E. William Street, Suite 101, Carson City, Nevada 89701 at least three days prior to the public workshop.

All persons that have requested in writing to receive the public meeting agenda have been duly notified by mail or e-mail.

---

Note: We are pleased to make reasonable accommodations for members of the public who are physically challenged and wish to attend the meeting. If special arrangements for the meeting are necessary, please notify the DHCFP, in writing, at 1100 East William Street, Suite 101, Carson City, or call Tanya Benitez at (775) 684-3730, as soon as possible, or e-mail at [tbenitez@dhcfp.nv.gov](mailto:tbenitez@dhcfp.nv.gov).

---